In its pursuit to conquer HCV, Pharco started researching for a cure to Hepatitis C (HCV), completed the largest phase IIIb clinical trial on Genotype 4 HCV Egyptian patients which was published and admired in the annual conferences of the most reputable worldwide liver associations (AASLD Nov 2015, CROI Feb 2016 & EASL April 2016), contracted with an Italian research and development laboratory to manufacture an affordable HCV treatment.
The treatment was made on a bioequivalence study that was based on WHO guidelines; that proved bioequivalence with the unaffordable innovator. Pharco and DNDi (Drugs for Neglected Diseases initiative) have conducted clinical trials on the rest of Genotypes to reach pangenotypic regimen in Malaysia and Thailand. To safeguard a continuous supply of raw materials of HCV treatments in collaboration with Italian scientists, Pharco established the first GMP compliant Active Pharmaceutical Ingredients (API) factory in Egypt starting with the production of Sofosbuvir with a non-infringing method.
Pharco Pharmaceuticals acquired 61% of Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Licensing a compound targeting the NS5A protein of HCV (Ravidasvir).
DNDi Licensed Ravidasvir in Low and Middle income countriess.
DNDi and Pharco conducted clinical trials in Malaysia and Thailand…